Mercury Laboratories Ltd: Valuation Shifts Signal Changing Price Attractiveness

Valuation Metrics: A Closer Look

As of 26 May 2026, Mercury Laboratories trades at ₹888.25, up from the previous close of ₹740.25, marking a 19.99% day gain. This surge has pushed the company’s P/E ratio to 21.35, a level that has transitioned its valuation grade from previously attractive to now fair. The price-to-book value stands at 1.91, reflecting a moderate premium over book value but still within reasonable bounds for a micro-cap pharmaceutical firm.

Other valuation multiples include an EV to EBIT of 18.83 and EV to EBITDA of 12.02, which are indicative of a company trading at a premium relative to its earnings before interest and taxes and earnings before interest, taxes, depreciation and amortisation. The EV to capital employed ratio is 1.86, while EV to sales is 1.44, both suggesting a balanced valuation compared to revenue and capital base.

The PEG ratio, a measure that adjusts the P/E ratio for earnings growth, remains attractive at 0.80, signalling that despite the price appreciation, the stock’s valuation relative to growth prospects is still reasonable. Dividend yield is modest at 0.39%, while return on capital employed (ROCE) and return on equity (ROE) stand at 9.20% and 8.95% respectively, reflecting moderate operational efficiency and shareholder returns.

Comparative Industry Analysis

When benchmarked against peers in the Pharmaceuticals & Biotechnology sector, Mercury Laboratories’ valuation appears more balanced. Several competitors such as Bliss GVS Pharma and NGL Fine Chem are classified as expensive, with P/E ratios of 25.71 and 36.97 respectively, and EV to EBITDA multiples well above 17. Mercury’s P/E of 21.35 and EV to EBITDA of 12.02 place it comfortably below these levels, suggesting it remains a more reasonably priced option within the sector.

However, some peers like Venus Remedies and Lincoln Pharma trade at fair valuations with P/E ratios of 19.92 and 16.34 respectively, and EV to EBITDA multiples close to Mercury’s. This indicates that Mercury Laboratories is now more in line with sector averages, losing some of its previous valuation discount.

Notably, companies such as Kwality Pharma and Shukra Pharma are deemed very expensive, with P/E ratios exceeding 30 and EV to EBITDA multiples above 20, underscoring the wide valuation spectrum within the sector.

Stock Performance Versus Market Benchmarks

Mercury Laboratories has outperformed the broader Sensex index across multiple time frames in recent months. Over the past week, the stock returned 16.84%, vastly exceeding the Sensex’s 1.56% gain. The one-month return is even more impressive at 24.54%, while the Sensex recorded a slight decline of 0.23% during the same period.

Year-to-date, Mercury Labs has delivered a 9.50% return, contrasting with the Sensex’s negative 10.25%. Over one year, the stock’s 5.31% gain again outpaces the Sensex’s 6.40% loss. However, longer-term performance over three and five years shows Mercury Labs lagging the Sensex, with returns of 2.69% and 13.59% respectively, compared to the Sensex’s 23.62% and 51.05%. Over a decade, Mercury Labs has delivered a robust 111.49% return, though still below the Sensex’s 195.54% gain.

This mixed performance profile suggests that while Mercury Laboratories has recently gained momentum, it remains a micro-cap stock with a more volatile and less consistent track record than the broader market.

Valuation Grade and Market Sentiment

MarketsMOJO’s latest assessment downgraded Mercury Laboratories’ Mojo Grade from Strong Sell to Sell on 22 May 2026, reflecting the shift in valuation from attractive to fair. The current Mojo Score stands at 31.0, signalling caution for investors amid the recent price surge. The company’s micro-cap status adds to the risk profile, as liquidity and volatility tend to be higher in this segment.

Investors should weigh the improved price performance against the stretched valuation multiples relative to historical levels. The P/E ratio of 21.35 is elevated compared to Mercury’s own past valuations but remains below many sector peers, suggesting some room for further upside if earnings growth materialises as expected.

Outlook and Investor Considerations

Mercury Laboratories’ recent price appreciation and valuation shift highlight a stock in transition. The move from attractive to fair valuation suggests that much of the positive sentiment and growth expectations may already be priced in. Investors should carefully analyse the company’s earnings trajectory, sector dynamics, and competitive positioning before committing fresh capital.

With a PEG ratio of 0.80, the stock still offers some valuation support relative to growth, but the modest dividend yield and moderate returns on capital indicate that operational improvements will be necessary to sustain momentum. The pharmaceutical sector remains competitive and subject to regulatory and innovation risks, which could impact future earnings.

Given Mercury Laboratories’ micro-cap classification and recent volatility, risk-averse investors may prefer to consider larger, more established peers or those with stronger valuation grades. Conversely, investors with a higher risk tolerance might view the current fair valuation as an entry point, provided they monitor earnings developments closely.

Overall, the stock’s recent rally and valuation realignment underscore the importance of balancing price appreciation with fundamental analysis in the Pharmaceuticals & Biotechnology sector.

Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →